Trial
NCT03520712
Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
BioMarin Pharmaceutical
Collaborators
—
Condition
Hemophilia A
Intervention
Valoctocogene Roxaparvovec
Why stopped
Early rollover into long-term extension study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-22